GSK's HIV prevention drug gets European marketing nod

[July 24, 2023]  (Reuters) - GSK Plc said on Monday that its HIV-focused unit ViiV Healthcare's cabotegravir injected drug and tablets got marketing authorisation from the European Medicines Agency.

Cabotegravir is recommended in combination with safer sexpractices for pre-exposure prophylaxis to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 35 kilogrammes, the company said.

(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Savio D'Souza)

A scientist works in a lab at the GSK Research and Development centre in Stevenage, Britain, February 21, 2023. REUTERS/Anna Gordon/File Photo

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.